![\"Pratip](\"https:\/\/www.med.unc.edu\/compmed\/wp-content\/uploads\/sites\/852\/2022\/05\/Pratip-Chattopadhyay.png\")
<\/p>\n<\/p>\n
Presenter: Dr. Pratip Chattopadhyay<\/p>\n
Talk Title: From Imagination to Implementation: The Development and Future of High Content Immune Analysis<\/p>\n
Abstract: Over the past 10-20 years, immunologists have driven a revolution in single-cell analysis. The combined advances in hardware, reagents, and software have revealed the incredible complexity of the immune system, setting the stage for powerful new studies of disease. This presentation reviews the field of single-cell analysis, discusses paradigm shifts in both technology development and the study of immune cells, and demonstrates how high content flow cytometry and molecular cytometry can contribute to biomarker discovery. The presentation concludes with a description of new solutions for the next generation of challenges in the field.<\/p>\n
Bio:
\nCEO, Talon Biomarkers
\nCSO, TerraFlow Bioinformatics
\nPratip Chattopadhyay is an internationally recognized leader in the experimental design, analysis, and interpretation of single-cell omics, having developed some of the most widely used approaches and tools in the field. He has led efforts in the development and application of polychromatic flow cytometry, immunoassays, and emerging single-cell technologies (both proteomic and transcriptomic), and is an acclaimed lecturer and teacher with global audiences.<\/p>\n
Pratip earned a Ph.D. in Molecular Microbiology and Immunology from Johns Hopkins Bloomberg School of Public Health and a B.A. in Biology from the University of Virginia. From 2003-to 2017 he was an NIH Staff Scientist working on the development of technologies for single-cell analysis and immunoassays, application to fundamental immunology, and immuno-monitoring in vaccine and disease pathogenesis settings. From 2017-to 2021 Pratip was the Associate Professor (Pathology) and Founding Director, Precision Immunology laboratory, NYU Langone Health, where his laboratory and core facility were focused on identifying changes to the immune system that correlated with or predicted disease outcome or therapeutic efficacy.<\/p>\n
Pratip is now leading two start-ups -Talon Biomarkers (CEO, Founder) and TerraFlow (CSO, Co-Founder). Talon Biomarkers is a biomarker discovery engine built to capture indicators of disease and therapy from a sea of immune cells. TerraFlow is a new data analysis platform that evaluates millions of phenotypes to identify the cell types that best predict patient outcomes, in a manner that is easy to explain, accessible, and highly interpretable.<\/p>\n","protected":false},"excerpt":{"rendered":"